Navigation Links
Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013
Date:2/4/2013

BOULDER, Colo., Feb. 4, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the second quarter of its fiscal year ending June 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

Array continued its evolution into a late-stage development company, making significant progress in generating data to support our upcoming development for our wholly-owned hematology programs.  During the quarter, Novartis declared its intention to begin a Phase 3 trial with MEK162 in NRAS melanoma which is now scheduled to start in April 2013. In addition, Novartis announced plans to pursue additional MEK162 late-stage clinical development in combination with their Raf inhibitor in BRAF mutant melanoma.  Also, AstraZeneca recently announced a potential start of a Phase 3 trial with selumetinib in non-small cell lung cancer (NSCLC) during the second half of 2013.Revenue for the second fiscal quarter ended December 31, 2012 was $18.4 million, compared to $23.2 million for the same period in fiscal 2012.  The decline in revenue was due to the $28.0 million licensing payment from Genentech during the first half of fiscal 2012 that did not recur in 2013.  Research and development expense was $13.9 million, compared to $13.2 million in the comparable prior year period.  Net loss was $10.9 million, or ($0.10) per share for the second quarter, compared to a net loss of $3.8 million, or ($0.06) per share, for the same period in fiscal 2012.

For the six months ended December 31, 2012, revenue was $34.2 million, compared to $45.4 million for the same period in fiscal 2012. The decline was also related to the Genentech licensing payment described above.  Net loss for the six months ended December 31, 2012, was $22.7 milli
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
2. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
3. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
4. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
5. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
6. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
7. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
8. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
9. John A. Orwin Joins Array BioPharma Board Of Directors
10. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
11. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/fhh9rj/technology ) ... Innovations in Smart Fabrics (Technical Insights)" report ... http://photos.prnewswire.com/prnh/20130307/600769 The Research Service titled ... assessment on technological advancements and market for Smart ... 1. The Smart Fabrics market is expected to ...
(Date:12/19/2014)... CAMBRIDGE, MA (PRWEB) December 18, 2014 ... adults in the United States suffer from one or ... arthritis, asthma, or cancer. Medication can address some of ... to daily activities that many sufferers face. While implanted ... surgery and stimulate the whole nerve, which can induce ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... dental biomaterial market will grow moderately through 2023 as ... and growing awareness of dental biomaterials all spur procedure ... such as China and ... bring dental procedures within reach for a larger proportion ...
(Date:12/17/2014)... Based on the revenues gained from surgical imaging ... by four major players contributing to approximately 74% ... GE Healthcare (U.K.), Siemens AG (Germany), Philips (Netherlands), ... Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The leading ... its strong product portfolio, which includes its flagship ...
Breaking Biology Technology:Technology Innovations in Smart Fabrics (Technical Insights) 2Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... Molecule Products for the Generation and Differentiation of ... and BOSTON, April 23 Fate ... Inc. announced today the formation of ... and biotechnology companies with the most advanced induced ...
... DFB Pharmaceuticals, Inc., has announced the promotion of Maxwell ... Corporate Finance. Mr. Lea was most recently Director ... DFB in 2002, Maxwell has positively impacted every level ... A. Patterson, Chief Financial Officer of DFB Pharmaceuticals. "I ...
... April 23 PRA International, a leading Clinical Research ... CRO 18th Annual Meeting April 28-30, 2009 in Orlando ... Partner will present " RFP Management & Contracting with ... Wednesday, April 29. Drawing on his extensive experience with ...
Cached Biology Technology:Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 2Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 3Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 4DFB Pharmaceuticals Appoints Maxwell Lea to Vice President Business Development and Corporate Finance 2PRA International Presents Key Budgeting Strategies at 18th Annual CRO Partnerships Conference 2
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... decades, climate scientists have worked to identify and measure key ... affect Earth,s climate. And they,ve been aided by ever more ... each type of pollutant more reliable. Yet the ... it -- continues to serve up surprises. The most recent? ...
... a breakthrough in the fight against the deadly Hendra virus ... to save the lives of people who become infected with ... the US has demonstrated that administering human monoclonal antibodies after ... virus, protected animals from challenge in a disease model. ...
... Germany, Oct. 30 SCM Microsystems, Inc. (Nasdaq: SCMM ... secure access, secure identity and secure exchange, announced today that ... common shares authorized during yesterday,s annual meeting of stockholders. ... 2009, 61 percent of SCM,s stockholders cast their votes and ...
Cached Biology News:Interactions with aerosols boost warming potential of some gases 2Interactions with aerosols boost warming potential of some gases 3Interactions with aerosols boost warming potential of some gases 4Breakthrough in fight against Hendra virus 2SCM Microsystems Announces Results of Annual Meeting 2
...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... Immunogen : Recombinant human ... 5mg/ml BSA, 0.15M NaCl, 0.05% ... of glycerol to 30% Quality ... on acid extracts of murine ...
Biology Products: